Potent inhibition of HTV-1 entry by (s4dU)35

被引:16
作者
Horváth, A
Tökés, S
Hartman, T
Waston, K
Turpin, JA
Buckheit, RW
Sebestyén, Z
Benkö, I
Bardos, TJ
Dunn, JA
Fésüs, L
Tóth, FD
Aradi, J
机构
[1] Univ Debrecen, Dept Biochem & Mol Biol, H-4012 Debrecen, Hungary
[2] Univ Debrecen, Res Ctr Mol Med, Med & Hlth Sci Ctr, Fac Med, H-4012 Debrecen, Hungary
[3] So Res Inst, Infect Dis Res, Frederick, MD 21701 USA
[4] Univ Debrecen, Dept Biophys, H-4012 Debrecen, Hungary
[5] Univ Debrecen, Cell Biophys Res Grp, Hungarian Acad Sci, H-4012 Debrecen, Hungary
[6] Univ Debrecen, Dept Pharmacol & Pharmacotherapy, H-4012 Debrecen, Hungary
[7] SUNY Buffalo, Dept Chem, Buffalo, NY 14260 USA
[8] OmniPharm Inc, Buffalo, NY 14207 USA
[9] Univ Debrecen, Dept Med Microbiol, H-4012 Debrecen, Hungary
基金
匈牙利科学研究基金会;
关键词
HIV-entry; inhibition; oligonucleotide; redox process; CD4;
D O I
10.1016/j.virol.2005.01.033
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We have previously reported the potent in vitro HIV-1 anti-reverse transcriptase activity of a 35-mer of 4-thio-deoxyuridylate [(s(4)dU)35]. In efforts to define its activity in a more physiological system, studies were carried out to determine the stage of viral infection that this compound mediates its anti-viral effect. Results of the studies reported herein show that (s(4)dU)(35) is nontoxic and is capable of inhibiting both single and multi-drug resistant HIV strains (IC50: 0.8-25.4 mu g/ml) in vitro. Besides its previously reported anti-RT activity, (s(4)dU)(35) mediated its antiviral action by preventing virus attachment (IC50: 0.002-0.003 mu g/ml), and was stable in vitro and slowly degraded by DNAses. Competition studies and fluorescence resonance energy transfer (FRET) experiments indicated that (s(4)dU)(35) preferentially binds to CD4 receptors, but not to CD48. Confocal laser scanning microscopy (CLSM) studies showed that (S(4)dU)(35) did not penetrate into the cells and colocalized with cell surface thioredoxin. Our studies identify (s(4)dU)(35) as a potential novel HIV entry inhibitor that may have utility as either a systemic antiretroviral or as a preventing agent for HIV transmission. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:214 / 223
页数:10
相关论文
共 51 条
[1]   INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS IN EARLY INFECTED AND CHRONICALLY INFECTED-CELLS BY ANTISENSE OLIGODEOXYNUCLEOTIDES AND THEIR PHOSPHOROTHIOATE ANALOGS [J].
AGRAWAL, S ;
IKEUCHI, T ;
SUN, D ;
SARIN, PS ;
KONOPKA, A ;
MAIZEL, J ;
ZAMECNIK, PC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (20) :7790-7794
[2]   Protein-disulfide isomerase-mediated reduction of two disulfide bonds of HIV envelope glycoprotein 120 occurs post-CXCR4 binding and is required for fusion [J].
Barbouche, R ;
Miquelis, R ;
Jones, IM ;
Fenouillet, E .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (05) :3131-3136
[3]   STRUCTURE-ACTIVITY-RELATIONSHIPS AND MODE OF ACTION OF 5-MERCAPTO-SUBSTITUTED OLIGO-NUCLEOTIDES AND POLYNUCLEOTIDES AS ANTITEMPLATES INHIBITING REPLICATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 [J].
BARDOS, TJ ;
SCHINAZI, RF ;
LING, KHJ ;
HEIDER, AR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (01) :108-114
[4]   Comparison of the toxicity of fluconazole and other azole antifungal drugs to murine and human granulocyte-macrophage progenitor cells in vitro [J].
Benkö, I ;
Hernádi, F ;
Megyeri, A ;
Kiss, A ;
Somogyi, G ;
Tegyey, Z ;
Kraicsovits, F ;
Kovács, P .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (05) :675-681
[5]   STRUCTURE-ACTIVITY AND CROSS-RESISTANCE EVALUATIONS OF A SERIES OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE 1-SPECIFIC COMPOUNDS RELATED TO OXATHIIN CARBOXANILIDE [J].
BUCKHEIT, RW ;
KINJERSKI, TL ;
FLIAKASBOLTZ, V ;
RUSSELL, JD ;
STUP, TL ;
PALLANSCH, LA ;
BROUWER, WG ;
DAO, DC ;
HARRISON, WA ;
SCHULTZ, RJ ;
BADER, JP ;
YANG, SS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (12) :2718-2727
[6]   POTENT AND SPECIFIC-INHIBITION OF HIV ENVELOPE-MEDIATED CELL-FUSION AND VIRUS BINDING BY G-QUARTET-FORMING OLIGONUCLEOTIDE (ISIS-5320) [J].
BUCKHEIT, RW ;
ROBERSON, JL ;
LACKMANSMITH, C ;
WYATT, JR ;
VICKERS, TA ;
ECKER, DJ .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 (11) :1497-1506
[7]   COMPARITIVE ANTI-HIV EVALUATION OF DIVERSE HIV-1-SPECIFIC REVERSE-TRANSCRIPTASE INHIBITOR-RESISTANT VIRUS ISOLATES DEMONSTRATES THE EXISTENCE OF DISTINCT PHENOTYPIC SUBGROUPS [J].
BUCKHEIT, RW ;
FLIAKASBOLTZ, V ;
DECKER, WD ;
ROBERSON, JL ;
STUP, TL ;
PYLE, CA ;
WHITE, EL ;
MCMAHON, JB ;
CURRENS, MJ ;
BOYD, MR ;
BADER, JP .
ANTIVIRAL RESEARCH, 1995, 26 (02) :117-132
[8]   THIAZOLOBENZIMIDAZOLE - BIOLOGICAL AND BIOCHEMICAL ANTIRETROVIRAL ACTIVITY OF A NEW NONNUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITOR [J].
BUCKHEIT, RW ;
HOLLINGSHEAD, MG ;
GERMANYDECKER, J ;
WHITE, EL ;
MCMAHON, JB ;
ALLEN, LB ;
ROSS, LJ ;
DECKER, WD ;
WESTBROOK, L ;
SHANNON, WM ;
WEISLOW, O ;
BADER, JP ;
BOYD, MR .
ANTIVIRAL RESEARCH, 1993, 21 (03) :247-265
[9]   Potent inhibition of HIV-1 fusion by cyanovirin-N requires only a single high affinity carbohydrate binding site: Characterization of low affinity carbohydrate binding site knockout mutants [J].
Chang, LC ;
Bewley, CA .
JOURNAL OF MOLECULAR BIOLOGY, 2002, 318 (01) :1-8
[10]  
CLANTON DJ, 1992, J ACQ IMMUN DEF SYND, V5, P771